Single-crystal X-ray study T = 293 K Mean '(C±C) = 0.005 A Ê R factor = 0.055 wR factor = 0.179 Data-to-parameter ratio = 20.6
# 2005 International Union of Crystallography Printed in Great Britain ± all rights reserved Valdecoxib [systematic name: 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide], C 16 H 14 N 2 O 3 S, a diaryl-substituted isoxazole, is a non-steroidal anti-in¯ammatory drug (NSAID) that is used for the treatment of rheumatoid arthritis, osteoarthritis and dysmenorrhea pain. The planar isoxazole ring is oriented at angles of 22.2 (1) and 54.3 (1) with respect to the phenyl and benzenesulfonamide groups, respectively. NÐHÁ Á ÁO and CÐHÁ Á ÁO hydrogen bonds and NÐHÁ Á Á%, CÐHÁ Á Á% and %±% interactions stabilize the crystal packing.
Comment
Valdecoxib, whose brand name is Bextra, is a nonsteroidal anti-in¯ammatory drug (NSAID) that is used for the treatment of osteoarthritis or rheumatoid arthritis and for the treatment of primary dysmenorrhea (Scheen & Malaise, 2004) . Valdecoxib is a potent and speci®c inhibitor of cyclooxygenase-2 (COX-2), an isoform of cyclo-oxygenase which is the key enzyme catalysing the inversion of arachidonic acid into prostaglandins and thromboxane (Coats et al., 2004) . COX-2 is an inducible enzyme that is primarily found in in¯ammatory cells and tissues and so the inhibition of this enzyme by valdecoxib does not affect the normal cells . Valdecoxib is a diaryl-substituted isoxazole that exhibits analgesic and antipyretic properties in addition to anti-in¯ammatory properties in animal models. These COX-2-selective diarylheterocyclic inhibitors have been reported to be a reversible competitive inhibitor of COX-1 while demonstrating time-dependent irreversible inhibition of COX-2, which accounts for the potency and selectivity demonstrated by members of this structural class (Walkeri et al., 2001) . The phenylsulphonamide moiety of the diarylheterocycles associate within a side pocket present in the active site of COX-2, and this pocket is more accessible in COX-2 than in COX-1, which is the result of the substitution of valine for isoleucine at position 523 in COX-1 (Kurumbail et al., 1996) .
In the title molecule, (I) (Fig. 1) , the isoxzaole ring (A) is planar and forms dihedral angles of 54.3 (1) and 22.2 (1) with the planes through the B (C6±C11) and C (C16±C21) benzene rings, respectively. The S atom in the sulphonamide group has sp 3 hybridization. Atom N15 forms an NÐHÁ Á ÁO hydrogen bond with atom O13 i [symmetry code: (i) (Fig. 2 ). An NÐHÁ Á Á% interaction between atom N15 and ring C of the symmetry-related molecule at (2 À x, y À 1 2 , 1 2 À z) occurs, with an NÁ Á Ácentroid (Cg) distance of 3.429 (4) A Ê . The isoxazole rings of the inversion-related molecules at (x, y, z) and (2 À x, 1 À y, 1 À z) interact via face-to-face %±% interaction, the CgÁ Á ÁCg distance being 3.606 (2) A Ê (Fig. 3) . In addition to the above interactions, the molecular packing in the crystal structure is further stabilized by a number of weak CÐHÁ Á ÁO and CÐ HÁ Á Á% interactions (Table 1 ; Cg1, Cg2 and Cg3 denote the centroids of rings A, B and C, respectively).
Experimental
Deoxybenzoin (0.01 M) was treated with hydroxylamine hydrochloride (0.01 M) in the presence of sodium acetate to produce the corresponding oxime. When the oxime was deprotonated using nbutyllithium (2 equivalents) and condensed with ethyl acetate (25 ml) the corresponding isoxazoline was produced. Chlorosulfonic acid (0.01 M) treatment followed by addition of sulfonyl chloride (0.01 M) with aqueous ammonia to the isoxazoline yielded valdecoxib. A view, down the a axis, of the NÐHÁ Á Á%, CÐHÁ Á Á% and %Á Á Á% interactions (dashed lines). Table 1 Hydrogen-bond geometry (A Ê , ). 
Crystal data
DÐHÁ Á ÁA D ÐH HÁ Á ÁA D Á Á ÁA D ÐHÁ Á ÁA(i) Àx 3 2 Y y 1 2 Y z; (ii) Àx 2Y y À 1 2 Y Àz 1 2 ; (iii) Àx 2Y Ày 1Y Àz 1; (iv) x À 1 2 Y Ày 1 2 Y Àz 1; (v) Àx 2Y y 1 2 Y Àz
